Kevin Harrington, MBBS, PhD of The Institute of Cancer Research, United Kingdom and Katharine A. Price, MD (Head and Neck Disease Group of the Mayo Clinic Comprehensive Cancer Cente, discuss the unmet need and current treatment landscape for recurrent/metastatic HPV16-positive HNSCC (head and neck squamous cell carcinoma) on a conference call to be held on June 17 at 12 pm. Webcast Link
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDSB:
- PDS Biotechnology Approves Equity Plan Amendment at Meeting
- Promising Phase 2 Trial Results Boost Confidence in PDS Biotechnology’s Versamune HPV for Advanced Head and Neck Cancer
- PDS Biotechnology to host KOL event on Versamune HPV
- PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO
- PDS Biotechnology unveils updated positive data from VERSATILE-002 trial